Mankind Pharma Ltd share price logo

Mankind Pharma Ltd Share Price

(MANKIND)

₹2151.5▲2.66%

as on 10:37AM, 12 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Mankind Pharma Ltd Performance

  • Day's Low

    Day's High

    ₹2,151.25
    Day's Price Range
    ₹2,229.8

  • 52 Week's Low

    52 Week's High

    ₹1,901.05
    52-Week Price Range
    ₹3,054.8
1 Month Return-8.77 %
3 Month Return-16.61 %
1 Year Return+ 3.26 %
Previous Close₹2,210.20
Open₹2,153.10
Volume4.01L
Upper Circuit-
Lower Circuit-
Market Cap₹91,188.11Cr

Mankind Pharma Ltd Key Statistics

P/E Ratio

43.41

PEG Ratio

5.57

Market Cap

₹91,188.11 Cr

P/B Ratio

9.56

EPS

48.47

Dividend Yield

0

Sector

Pharmaceuticals

ROE

20.95

Mankind Pharma Ltd Analyst Rating

based on 16 analysts

BUY

75.00%

Buy

12.50%

Hold

12.50%

Sell

Based on 16 analysts offering long term price targets for Mankind Pharma Ltd. An average target of ₹2804.5

Source: S&P Global Market Intelligence

Mankind Pharma Ltd Share analysis

Mankind Pharma Ltd price forecast by 16 analysts

Upside of26.89%

High

₹3300

Target

₹2804.50

Low

₹2150

Mankind Pharma Ltd target price ₹2804.5, a slight upside of 26.89% compared to current price of ₹2151.5. According to 16 analysts rating.

Source: S&P Global Market Intelligence

Key events for Mankind Pharma Ltd

  • Mankind Pharma Announces Competitive Pricing for Empagliflozin - 10 Mar, 2025

    Mankind Pharma intends to offer Empagliflozin at a significantly reduced price of Rs 9–14 per tablet, aiming to disrupt the diabetes drug market. However, shares fell 2.38% to Rs 2,260.25.

  • Mankind Pharma Faces Significant Tax Demand - 03 Mar, 2025

    Mankind Pharma has received an income tax demand order totaling ₹111.68 crore for the assessment year 2021-22, negatively impacting market sentiment.

  • Mankind Pharma Gains NCLT Approval and MSCI Recognition - 28 Feb, 2025

    Mankind Pharma received NCLT approval for the amalgamation of Shree Jee Lab, JPR Labs, and Jaspack Industries. The company also joined the top ten weight increases in MSCI Standard Indexes.

  • Mankind Pharma Focuses on Ownership and New Drug Launch - 26 Feb, 2025

    Mankind Pharma's CEO highlights the importance of ownership to improve execution speed. The company also plans to launch a generic Semaglutide next year.

  • IPA Highlights Role of Generic Drug Producers - 19 Feb, 2025

    The Indian Pharmaceutical Alliance (IPA) represents 23 research-based pharma companies, including Mankind Pharma, contributing over 80% to drug exports and servicing 64% of the domestic market.

  • Mankind Pharma Sells Subsidiary to Reduce Debt - 10 Feb, 2025

    Mankind Pharma Ltd. has approved the sale of its entire stake in Mahananda Spa and Resorts to Chalet Hotels for ₹530 crore, aiming to retire part of its debt. The transaction is expected to be completed by February 28, 2025.

Insights on Mankind Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 6.99% to 7.83% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 2.53K Cr → 3.31K Cr (in ₹), with an average increase of 8.4% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 2.86% to 2.90% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 12.37% to 13.34% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MANKIND stock has moved down by -1.1%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 74.87% to 72.71% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 653.47 Cr → 380.23 Cr (in ₹), with an average decrease of 41.8% per quarter

Mankind Pharma Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,606.95Cr (-)₹2,441.10Cr (↓6.36%)₹2,893.42Cr (↑18.53%)₹3,076.51Cr (↑6.33%)₹3,230.00Cr (↑4.99%)
Net Income₹459.81Cr (-)₹476.59Cr (↑3.65%)₹543.07Cr (↑13.95%)₹658.88Cr (↑21.33%)₹384.52Cr (↓41.64%)
Net Profit Margin17.64% (-)19.52% (↑10.66%)18.77% (↓3.84%)21.42% (↑14.12%)11.90% (↓44.44%)
Value in ₹ crore
Details2021202220232024
Total Assets₹5,989.77Cr (-)₹9,103.97Cr (↑51.99%)₹9,634.50Cr (↑5.83%)₹11,765.16Cr (↑22.11%)
Total Liabilities₹1,255.50Cr (-)₹2,563.52Cr (↑104.18%)₹1,850.59Cr (↓27.81%)₹2,141.35Cr (↑15.71%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹959.61Cr (-)₹983.38Cr (↑2.48%)₹821.44Cr (↓16.47%)₹1,798.99Cr (↑119.00%)₹1,982.97Cr (↑10.23%)

Index Inclusions

BSE Healthcare

₹38,999.75

-0.83 (▲-326.55%)

S&P BSE 250 LargeMidCap

₹9,526.00

-0.36 (▲-34.55%)

S&P BSE Largecap

₹8,589.40

-0.34 (▲-29.45%)

S&P BSE 100 LargeCap TMC

₹8,244.05

-0.32 (▲-26.22%)

Nifty LargeMidcap 250

₹14,025.50

-0.43 (▲-61.05%)

NIFTY PHARMA

₹20,183.80

-0.73 (▲-148.3%)

Nifty 500

₹20,236.80

-0.32 (▲-65.7%)

Nifty 200

₹12,306.05

-0.44 (▲-54.05%)

Nifty Midcap 150

₹17,984.95

-0.67 (▲-121.95%)

BSE 200

₹10,068.90

-0.43 (▲-43.56%)

Nifty MidSmallcap 400

₹16,638.65

-0.44 (▲-72.95%)

Nifty Midcap 100

₹48,347.00

-0.85 (▲-415.75%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

BSE 500

₹31,881.05

-0.35 (▲-110.55%)

Mankind Pharma Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
72.71%
-2.89
Foreign Institutions
13.34%
7.85
Mutual Funds
7.83%
12.07
Retail Investors
2.9%
1.35
Others
3.23%
10.67

Mankind Pharma Ltd Key Indicators

Details2024
Book Value Per Share (₹)233.73
Details2024
Earning Per Share (₹)48.47
Details20202021202220232024
Return On Equity %28.5325.8624.6517.4320.95
Details2021202220232024
Return On Assets %21.1315.7513.316.26

Mankind Pharma Ltd Valuation

Mankind Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (40.63x)

August 5, 2024

Today (43.41x)

March 11, 2025

Industry (50.65x)

March 11, 2025

Highest (57.70x)

January 3, 2025

LowHigh

Mankind Pharma Ltd Earnings and Dividends

  • Mankind Pharma Ltd Earnings Results

    Mankind Pharma Ltd’s net profit fell -16.2% since last year same period to ₹380.23Cr in the Q3 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated -41.81% fall in its net profits since last 3-months.

    Read More about Earnings Results

Mankind Pharma Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Mankind Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Mankind Pharma Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Mankind Pharma Ltd
Mankind Pharma Ltd
BUY₹91,188.11 Cr11.08%0.51₹1,941 Cr₹10,334 Cr
Cipla Ltd
Cipla Ltd
BUY₹1,16,760.93 Cr53.25%0.50₹4,155 Cr₹25,774 Cr
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd
HOLD₹93,178.20 Cr19.18%0.52₹5,577 Cr₹28,011 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹90,545.97 Cr55.97%0.64₹3,854 Cr₹19,547 Cr
Divis Laboratories Ltd
Divis Laboratories Ltd
HOLD₹1,47,235.51 Cr37.99%0.50₹1,600 Cr₹7,845 Cr
See all

About Mankind Pharma Ltd

Mankind Pharma Ltd. was established in 1991 as a Private Limited Company. In 2005 it was converted to a Public Limited Company and the name changed to Mankind Pharma Limited. The Company is engaged in the development, manufacturing and marketing of a range of pharmaceuticals and consumer healthcare products, and is active in acute and chronic therapeutic areas such as anti-infectives, cardiovascular and gastrointestinal treatments, antidiabetic and neuro/CNS medicines, vitamins, minerals and nutrients. In 2004, they entered the chronic pharmaceutical segment, and have added further products over the years, including ophthalmic products, consumer healthcare products, animal healthcare products and specialty therapeutic divisions. They operate 23 manufacturing facilities across India and had 2181 manufacturing personnel as of March 31, 2021. It is now planning to raise capital through the public offering of 40058844 equity shares, with a total installed capacity of 40.77 billion units across a range of products.

Share Price: ₹2151.50 per share as on 12 Mar, 2025 10:37 AM
Market Capitalisation: ₹91,188.11Cr as of today
Revenue: ₹3,230.00Cr as on December 2024 (Q4 24)
Net Profit: ₹384.52Cr as on December 2024 (Q4 24)
Listing date: 09 May, 2023
Chairperson Name: RAMESH CHAND JUNEJA
OrganisationMankind Pharma Ltd
HeadquartersNew Delhi
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Mankind Pharma Ltd

What is Mankind Pharma Ltd price today?

Mankind Pharma Ltd share price today stands at ₹2151.5, Open: ₹2153.1, Previous Close: ₹2210.2, High: ₹2229.8, Low: ₹2151.25, 52 Week High: ₹3054.8, 52 Week Low: ₹1901.05.

How to Buy Mankind Pharma Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Mankind Pharma Ltd shares

Is Mankind Pharma Ltd listed on NSE?

Mankind Pharma Ltd is listed on NSE

Is Mankind Pharma Ltd listed on BSE?

Mankind Pharma Ltd is listed on BSE

What are today's High and Low prices of Mankind Pharma Ltd?

  • Today's highest price of Mankind Pharma Ltd is ₹2229.8.
  • Today's lowest price of Mankind Pharma Ltd is ₹2151.25.

What are today's traded volumes of Mankind Pharma Ltd?

Today's traded volume of Mankind Pharma Ltd(MANKIND) is 4.01L.

What is today's market capitalisation of Mankind Pharma Ltd?

Today's market capitalisation of Mankind Pharma Ltd(MANKIND) is ₹91188.11Cr.

What is the 52 Week High and Low Range of Mankind Pharma Ltd?

Mankind Pharma Ltd (MANKIND)
Price
52 Week High
₹3054.8
52 Week Low
₹1901.05

How much percentage Mankind Pharma Ltd is down from its 52 Week High?

Mankind Pharma Ltd (MANKIND) share price is ₹2151.5. It is down -29.57% from its 52 Week High price of ₹3054.8

How much percentage Mankind Pharma Ltd is up from its 52 Week low?

Mankind Pharma Ltd (MANKIND) share price is ₹2151.5. It is up 13.17% from its 52 Week Low price of ₹1901.05

What are the historical returns of Mankind Pharma Ltd?

Mankind Pharma Ltd (MANKIND)
Returns
1 Day Returns
-58.7%
1 Month Returns
-8.77%
3 Month Returns
-16.61%
1 Year Returns
3.26%

What is the PE ratio of Mankind Pharma Ltd today?

PE Ratio of Mankind Pharma Ltd is 43.41

PE ratio = Mankind Pharma Ltd Market price per share / Mankind Pharma Ltd Earnings per share